Venatorx Pharmaceuticals

[Not Yet Scheduled]
Founded in 2010, Venatorx Pharmaceuticals is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections. Venatorx has built a world-class in-house research and development organization that has filed over 120 patents. Venatorx’s two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam / beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively. In addition, the first Venatorx antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor, is in Phase 1 clinical development. The Company also has discovery-stage programs targeting a novel class of non-beta-lactam antibiotics called Penicillin Binding Protein (PBP) inhibitors that have the potential to circumvent 70+ years of resistance and usher in a new wave of antibacterial therapeutics.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2010
Main Therapeutic Focus:
Lead Product in Development:
Cefepime-taniborbactam
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
President and CEO
Venatorx Pharmaceuticals, Inc.